Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00298714
Status:
COMPLETED
Last Update Posted:
2007-11-22
First Post:
2006-03-02
Brief Title:
Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
Sponsor:
Hospital Clinic of Barcelona
Organization:
Hospital Clinic of Barcelona
Study Overview
Official Title:
Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is evidence on the beneficial effects of the administration of angiotensin II type 1 AT1 receptors antagonists on liver fibrosis in hepatic stellate cells experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis
The purpose of this study is to investigate the effect of long-term administration of oral Losartan an AT1 receptor antagonist on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 METAVIR score
The purpose of this study is to investigate the effect of long-term administration of oral Losartan an AT1 receptor antagonist on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 METAVIR score
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Protocol number 02-0491 | None | None | None |